Русский / English
Enter the query
News
Press Center
phone: +7 495 785 29 07
fax: +7 499 230 32 94
press@interros.ru
Contacts
The Russian tokenization platform Atomyze, where Vladimir Potanin's Interros is one of the investors, received the operator status of an information system for managing digital financial assets (DFA) from the Central Bank. In accordance with the recently adopted law on DFA in Russia, the regulator granted the rights to issue and circulate DFA in exchange for Russian rubles, as well as to store DFA, maintain a register of holders and to support electronic accounts and channels for servicing DFA holders. More Topics Atomyze / Vladimir Potanin / Interros / DFA
22.07.2020
A Russian original medication called Polyoxidonium® by Petrovax, a pharmaceutical company affiliated to the Interros Group, has passed the first phase of an international clinical trial for its effectiveness and safety for COVID-19 treatment.
More Topics Petrovax Pharm
17.04.2020
Polyoxidonium (azoximer bromide) - the Russian original drug produced by Petrovax-  was approved by the Ministry of Health of the Russian Federation for conducting an international clinical trial for the treatment of COVID-19.
More Topics Petrovax Pharm
03.12.2018
The first place in the nomination «Medicine of choice for the treatment and prevention of SARS and influenza among children» was granted to «Polyoxidonium», produced by NGO Petrovax Pharm.
More Topics Petrovax Pharm
06.08.2018
In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.
More Topics Petrovax Pharm